EIDD-2801/MK-4482(莫努匹拉韦)加速首次人体临床试验:一种对SARS-CoV-2有强效抗病毒活性的核糖核苷类似物
本文报告了申办方、合同研究组织(CRO)与监管机构之间前所未有的合作,使莫努匹拉韦的首次人体(FIH)试验在获得英国监管批准后5天内给药。在约16周内完成了8个单次递增剂量(SAD)队列、7个多次递增剂量(MAD)队列和1个食物效应(FE)队列的健康志愿者给药,而标准行业时间线约需46周。该研究数据支持在初始方案提交后8周内向美国FDA提交2/3期临床试验方案,并允许在额外两周内启动2期研究。
要点
- 莫努匹拉韦首次人体试验在获得英国监管批准后5天内完成首剂给药。
- SAD、MAD和FE队列在约16周内完成,而标准时间线约需46周。
- 加速流程未牺牲安全性,数据支持快速启动2/3期试验。
核心结论
- 在全球大流行背景下,申办方、CRO与监管机构的协作模式可加速临床数据产生而不损害安全性。
研究设计与样本
- 随机、双盲、安慰剂对照的首次人体试验,包含单次递增剂量(SAD)、多次递增剂量(MAD)和食物效应(FE)队列。
- 每个队列按6:2活性药物与安慰剂比例随机分配。
- FE队列纳入10名受试者,随机先后接受空腹或餐后给药以完成每个受试者的空腹和餐后序列。
- 剂量递增决策加速,MAD队列在全部SAD队列完成前启动,条件为MAD队列总日剂量不超过SAD队列中已证明安全且耐受良好的剂量。
主要发现
- 在初始方案提交至研究伦理委员会(REC)和英国药品和健康产品管理局(MHRA)后约16周内,完成了8个SAD队列、7个MAD队列和1个FE队列的健康志愿者给药。
- 按标准行业时间线,首次人体研究约需46周完成,并需33周才能启动2期给药。
- 本研究数据支持在初始方案提交后8周内向美国FDA提交2/3期临床试验方案,FDA意见允许在额外两周内启动2期研究。
临床怎么用
- 该协作模式可为大流行应急条件下的临床开发提供加速路径参考。
- 加速剂量递增和队列启动需以SAD队列的安全性耐受性数据为前提。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Here, we report an unprecedented collaboration between sponsor, contract research organization (CRO), and regulatory authorities that enabled accelerated generation of these phase I data, including administration of the first-in-human (FIH) dose of molnupiravir within 5 days of receiving regulatory approval in the United Kingdom (UK). Single and multiple ascending dose (SAD and MAD, respectively) cohorts were dosed in randomized, double-blind, and placebo-controlled fashion, with a 6:2 active-to-placebo ratio in each cohort. A food-effect (FE) cohort included 10 subjects who were randomized to receive drug in the fasted or fed state followed by the fed or fasted state to complete a fed and fasted sequence for each subject. Dose escalation decisions were accelerated and MAD cohorts were initiated prior to completion of all SAD cohorts with the provision that the total daily dose in a MAD cohort would not exceed a dose proven to be safe and well-tolerated in a SAD cohort. Dosing in healthy volunteers was completed for eight single ascending dose (SAD) cohorts, seven multiple ascending dose (MAD) cohorts, and one food-effect (FE) cohort within approximately 16 weeks of initial protocol submission to the Research Ethics Committee (REC) and Medicines and Healthcare products Regulatory Agency (MHRA). Working to standard industry timelines, the FIH study would have taken approximately 46 weeks to complete and 33 weeks to enable phase 2 dosing. Data from this study supported submission of a phase 2/3 clinical trial protocol to the US Food and Drug Administration (FDA) within 8 weeks of initial protocol submission, with FDA comments permitting phase 2 study initiation within two additional weeks. In the setting of a global pandemic, this model of collaboration allows for accelerated generation of clinical data compared to standard processes, without compromising safety.
引用
- Holman W, Holman W, McIntosh S, et al. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. Trials. 2021. PMID: 34425873. doi:10.1186/s13063-021-05538-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。